Risk factors for synchronous primary endometrial and ovarian cancers. 2001

L J Herrinton, and L F Voigt, and N S Weiss, and S A Beresford, and P A Wingo
Division of Research, Kaiser Permanente, Oakland, CA 94611, USA.

OBJECTIVE The incidence of synchronous primary endometrial and ovarian cancer is 2- to 10-fold higher than that expected based on the incidence of each cancer alone. We sought to evaluate reasons for this in a case-control study. METHODS We combined data on a maternal history of cancer and reproductive and menstrual factors from 56 women with synchronous multiple primary disease who had participated in three population-based studies of gynecologic cancer. For comparison, we analyzed the same information from 280 women with endometrial cancer alone, 280 with ovarian cancer alone, and 280 without a history of either cancer. RESULTS The reduced risk of multiple primary disease associated with high parity (2 or more births vs 0: OR = 0.37, 95% Cl, 0.19-76) and long-term use of oral contraceptives (12 or more months vs none: OR = 0.60, 95% Cl, 0.24-1.5) tended to be more pronounced than that associated with endometrial cancer alone or with ovarian cancer alone. CONCLUSIONS Though limited by relatively small numbers, our results suggest that the presence of some common etiologies is a basis for the unusually high co-occurrence of endometrial and ovarian cancers.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009378 Neoplasms, Multiple Primary Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites. Neoplasms, Synchronous,Neoplasms, Synchronous Multiple Primary,Multiple Primary Neoplasms,Multiple Primary Neoplasms, Synchronous,Synchronous Multiple Primary Neoplasms,Synchronous Neoplasms,Multiple Primary Neoplasm,Neoplasm, Multiple Primary,Neoplasm, Synchronous,Primary Neoplasm, Multiple,Primary Neoplasms, Multiple,Synchronous Neoplasm
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D014861 Washington State bounded by on the north by Canada, on the east by Idaho, on the south by Oregon, and on the west by the Pacific Ocean.
D015914 Estrogen Replacement Therapy The use of hormonal agents with estrogen-like activity in postmenopausal or other estrogen-deficient women to alleviate effects of hormone deficiency, such as vasomotor symptoms, DYSPAREUNIA, and progressive development of OSTEOPOROSIS. This may also include the use of progestational agents in combination therapy. Hormone Replacement Therapy, Post-Menopausal,Postmenopausal Hormone Replacement Therapy,Replacement Therapy, Estrogen,Estrogen Progestin Combination Therapy,Estrogen Progestin Replacement Therapy,Estrogen Replacement,Replacement, Estrogen,Therapy, Estrogen Replacement,Estrogen Replacement Therapies,Estrogen Replacements,Hormone Replacement Therapy, Post Menopausal,Replacement Therapies, Estrogen,Replacements, Estrogen,Therapies, Estrogen Replacement

Related Publications

L J Herrinton, and L F Voigt, and N S Weiss, and S A Beresford, and P A Wingo
January 2006, European journal of gynaecological oncology,
L J Herrinton, and L F Voigt, and N S Weiss, and S A Beresford, and P A Wingo
March 2014, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,
L J Herrinton, and L F Voigt, and N S Weiss, and S A Beresford, and P A Wingo
November 2015, The journal of obstetrics and gynaecology research,
L J Herrinton, and L F Voigt, and N S Weiss, and S A Beresford, and P A Wingo
October 2016, Tumori,
L J Herrinton, and L F Voigt, and N S Weiss, and S A Beresford, and P A Wingo
April 2009, Obstetrics and gynecology,
L J Herrinton, and L F Voigt, and N S Weiss, and S A Beresford, and P A Wingo
June 2012, Nihon rinsho. Japanese journal of clinical medicine,
L J Herrinton, and L F Voigt, and N S Weiss, and S A Beresford, and P A Wingo
January 2010, European journal of gynaecological oncology,
L J Herrinton, and L F Voigt, and N S Weiss, and S A Beresford, and P A Wingo
January 2003, European journal of gynaecological oncology,
L J Herrinton, and L F Voigt, and N S Weiss, and S A Beresford, and P A Wingo
December 1993, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics,
L J Herrinton, and L F Voigt, and N S Weiss, and S A Beresford, and P A Wingo
March 1996, American journal of clinical pathology,
Copied contents to your clipboard!